Gi-Young Sohn
Chief Executive Officer bei ENZYCHEM LIFESCIENCES CORPORATION
Vermögen: 6 Mio $ am 30.04.2024
Profil
Gi-Young Sohn is currently the Chief Executive Officer & Director at ENZYCHEM LIFESCIENCES Corp.
since 2012.
He is also the Chairman at Bridget Lifesciences Corp.
since 2003.
Mr. Sohn has an undergraduate and graduate degree from Korea University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 07.05.2024 | 4 069 430 ( 4,78% ) | 6 Mio $ | 30.04.2024 |
Aktive Positionen von Gi-Young Sohn
| Unternehmen | Position | Beginn |
|---|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Chief Executive Officer | 01.06.2012 |
Bridget Lifesciences Corp.
 Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Chairman | 01.01.2003 |
Ausbildung von Gi-Young Sohn
| Korea University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
| ENZYCHEM LIFESCIENCES Corp. | |
Bridget Lifesciences Corp.
Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Finance |
